Sodium Hyaluronate Research Articles (Page 1)

To evaluate the stability of two ophthalmic gels-one containing carbomer alone (Ocry-gel), and the other combining carbomer with sodium hyaluronate (Eye Lube Pro)-on the corneal surface of anesthetized dogs, using spectral-domain optical coherence tomography (SD-OCT) to quantify Central Tear Film Thickness (CTFT) over time. Twenty healthy dogs undergoing general anesthesia for non-ocular routine procedures were included in a randomized controlled study. Each dog received Ocry-gel in one eye and Eye Lube Pro in the contralateral eye, according to a randomization protocol. CTFT was measured with ultrahigh-resolution anterior segment SD-OCT before (T0) and after (T1) administration of 200 μL of each gel, then at 10, 15, 20, 25, 30, 35, 40, 45, 50, and 60 min. CTFT evolution was analyzed by two-way repeated-measures ANOVA with normality testing and non-parametric correction when required. CTFT profiles significantly differed between formulations. Eye Lube Pro exhibited more sustained thickness than Ocry-gel. After 60 min, CTFT remained measurable in 14/20 dogs for Eye Lube Pro versus 2/20 for Ocry-gel. Statistical analysis confirmed significantly higher CTFT for Eye Lube Pro at most time points (p < 0.001). No significant influence of sex, age, or brachycephalic phenotype was observed. Addition of sodium hyaluronate to a carbomer-based gel significantly prolongs pre-corneal retention time in anesthetized dogs. These results suggest that selecting the protective gel should consider anesthesia duration or guide adjustment of administration frequency.

Innovative bilayered buccal films: A paediatric-friendly dosage form for transmucosal azithromycin delivery.

This survey reports on the current practice and management of hemorrhagic cystitis (HC) among the EBMT centers. The survey response rate was 27%. The diagnostic search of BK polyomavirus (BKPyV) was available in 93% of centers and performed in urine (100%), blood/plasma (51%), and serum (12%). Patient screening for BKPyV infection was performed in 14% of centers before hematopoietic cell transplantation (HCT). In comparison, surveillance for BKPyV infection was performed after HCT in 39% of centers, mainly with a frequency of 1-2 times/week. Preventative measures are based mainly on hyperhydration and sodium 2-mercaptoethanesulphonate (Mesna), while the use of bladder catheter is limited; moreover, 23% of centers used quinolones prophylaxis.The primary therapeutic interventions are hyperhydration, Mesna, analgesics, and sustained platelet transfusions; bladder irrigation by urinary catheter is adopted by 47-50% of centers. In the case of BKPyV infection, 85% of centers use intravenous or intrabladder administration of cidofovir at a dosage ranging from 1 to 5 mg/kg. Centers report a miscellaneous range of alternative therapeutic measures (adoptive immunotherapy, hyperbaric oxygen therapy, fibrin glue/platelet-rich plasma, leflunomide, sodium hyaluronate) and the need for invasive procedures. This survey confirms that the management of HC needs further education, clinical research, and innovation.

Sodium hyaluronate-modified FeIII-shikonin self-assembly nanoparticle for effective tumor therapy and reduced tumor metastasis.

To describe in-office suprachoroidal viscopexy (SCVEXY) as a novel adjunct surgical technique with pneumatic retinopexy (PnR) for rhegmatogenous retinal detachment (RRD). A 61-year-old pseudophakic man who was failing PnR for a macula-involving RRD underwent rescue SCVEXY at St. Michael's Hospital, Unity Health Toronto, Toronto, Canada. An injection of suprachoroidal sodium hyaluronate 2.3% (Healon 5, Johnson & Johnson Vision) was performed at five o'clock under the causative retinal tear using a 30 G needle with a custom-made guard that exposed 1 mm of the needle. Following the procedure, a dome-shaped suprachoroidal convexity was present in the inferotemporal quadrant. The patient achieved complete reattachment over 2 days with continued positioning. Laser retinopexy was applied around the causative tear, and the viscoelastic reabsorbed over a period of approximately 2 weeks. The retina remained attached until the final follow-up at 9 months. Suprachoroidal viscopexy (SCVEXY) is a minimally invasive in-office procedure that creates a temporary suprachoroidal buckle that can be used to rescue failing PnR in RRD. It can be particularly useful to close inferior tears, avoiding the need for operating room procedures such as pars plana vitrectomy or scleral buckle. However, there are still limited data on ideal case selection, efficacy, adverse events, and failure rates.

The object of the study is the properties of a biopolymer system for prolonged delivery of cosmeceutical active ingredients based on natural polysaccharides (sodium hyaluronate and chitosan). The work solves the problem of the lack of a methodology for predicting the properties of a biopolymer system at the design stage. This methodology should link its component composition with functional and structural-mechanical characteristics. The optimization criterion should be achieving a controlled release profile of the hydrophilic active (dexpanthenol) without an initial "explosive" effect. It was established that the optimal ratio is 2.5% sodium hyaluronate and 1.2% chitosan, which ensures the release of 30–35% of dexpanthenol in 6 hours and 60–65% – in 24 hours. Structural and mechanical analysis confirmed the formation of a stable gel with a viscosity of 9800 ± 250 mPa·s and a storage modulus of 325 Pa. This is explained by the formation of a dense polyelectrolyte network due to electrostatic interactions between the anionic groups of sodium hyaluronate. The results of the study of the biopolymer system include the development of approximation models. These models predict the release profile of dexpanthenol based on the concentration of polymers and evaluate the structural and mechanical properties of the biopolymer system. The results obtained can be used in the cosmeceutical industry to create gel products with prolonged action. The effectiveness of the system was confirmed in vitro in phosphate buffer solution (pH 7.4; 37°C). The criterion for effectiveness was the achievement of a controlled release profile: 30–35% of the active substance in 6 hours and 60–65% in 24 hours, which provides a long-term effect without an initial “explosive” effect

Efficacy of 0.38% and 0.18% sodium hyaluronate ocular lubricants for dry eye: A randomized trial in adult gazan participants.

ABSTRACTBackgroundIn recent years, the demand for sophisticated aesthetic solutions and the emergence of novel materials in cosmetic dermatology have increased substantially. However, these materials induce marked inflammatory reactions. To address this limitation, in this study, we developed a novel filler Cross‐Linked Sodium Hyaluronate Gel combined with Polyvinyl Alcohol Microspheres (PVA/HA filler) and systematically evaluated its effects on the periosteum and subcutaneous tissue in a rat model.MethodsUltrasound, histopathology, and molecular biological assays were employed to systematically assess the shape retention of the PVA/HA filler and its biological responses at 1, 3, and 6 months in the periosteum and subcutaneous tissues.ResultsExperimental data demonstrated that the PVA/HA filler exhibited excellent structural support, with no significant morphological changes observed over the 6‐month observation period. Notably, the filler effectively promoted periosteal angiogenesis and enhanced proliferation of collagen and elastic fibers. Furthermore, it maintained low inflammatory responses, even with increased microsphere concentrations in the PVA/HA formulation.ConclusionsThe novel PVA/HA filler demonstrated strong structural support in both the periosteum and subcutaneous tissue. The filler provides enhanced periosteal angiogenesis, promotes periosteal thickening, and stimulates collagen fiber formation, while exhibiting minimal inflammation, high safety, and no risk of hyperplasia.

This study aimed to unveil the impact of optimal pulse technology (OPT) combined with tobramycin and dexamethasone eye ointment on the ocular surface disease index (OSDI) and related outcomes in patients with blepharokeratoconjunctivitis (BKC). Ninety-six BKC patients treated at our hospital from September 2022 to September 2023 were divided into a control group (n = 48) and an observation group (n = 48) by a random number table. Both groups received fluorometholone and sodium hyaluronate eye drops. The control group additionally applied tobramycin and dexamethasone eye ointment to the lid margin twice daily, while the observation group underwent OPT on this basis. The clinical efficacy and safety, OSDI, conjunctival hyperemia score, lid margin alteration score, meibomian gland yield secretory score (MGYSS), Demodex mite count, and tear break-up time (TBUT) were compared between the two groups before treatment and at 4 and 8 weeks post-treatment. Additionally, the National Eye Institute Visual Function Questionnaire-25 (NEIVFQ-25) scores were assessed before and after treatment. The total effective rate in the observation group was 100.00% (48/48) at 8 weeks post-treatment, higher than 89.58% (43/48) in the control group (P < 0.05). The OSDI, conjunctival hyperemia score, lid margin alteration scores, MGYSS, and Demodex mite count all decreased in both groups at 4 and 8 weeks post-treatment compared to baseline, with greater improvements in the observation group(P < 0.05). TBUT and NEIVFQ-25 scores increased in both groups at 8 weeks post-treatment compared to baseline, with the observation group achieving better outcomes than the control group (P < 0.05). The addition of OPT to standard therapy for BKC is safe and provides superior short-term efficacy. It can alleviate lid margin inflammation, improve ocular surface symptoms, and enhance visual-related quality of life.

Bacterial infections, particularly those caused by multidrug-resistant (MDR) bacteria, pose a serious global health threat. The limited efficacy of traditional antibiotic drugs against MDR strains and the slow development of antibiotics necessitate the exploration of alternative therapeutic strategies. Acid-degradable metallic peroxide has emerged as a promising solution, exhibiting broad-spectrum antimicrobial activity with a reduced risk of resistance development. In this study, we have constructed an acid-responsive bimetallic peroxide nanocomposite (ZCS@M@HA) for the treatment of wound infections involving methicillin-resistant Staphylococcus aureus (MRSA). In our design, the copper-doped zinc peroxide (ZC) nanoparticles are prepared and coated with mesoporous silica to obtain core-shell structured ZC@M, which is subsequently loaded with S-nitroso-N-acetylpenicillamine (SNAP) acting as a nitric oxide (NO) donor and capped with sodium hyaluronate (HA) to prevent premature SNAP release. In the acidic microenvironment of infectious sites, ZCS@M@HA releases Zn2+, Cu2+, and H2O2, and the former disrupts bacterial energy metabolism by impairing the electron transport chain. Meanwhile, self-supplied H2O2 and Cu2+ perform a Fenton-like reaction to generate highly toxic hydroxyl radicals (•OH) for damaging bacterial membranes. Moreover, Cu2+ depletes intracellular glutathione (GSH) to augment the oxidative stress. Furthermore, NO released from SNAP triggered by Cu2+ and GSH accelerates wound healing by promoting collagen deposition, tissue regeneration, and vascularization. In vivo assays demonstrate the high MRSA inhibition efficacy of ZCS@M@HA with optimal wound healing. The proposed acid-responsive ZCS@M@HA with multi-bactericidal modalities offers an effective approach to fight MDR bacteria and presents a promising strategy for treating wound infections.

PDGF-BB inhibits F-actin formation and chondrocyte dedifferentiation in osteoarthritis via oxygen-dependent HIF-1α/SCIN regulation and RhoA/ROCK signaling inhibition.

Background Periorbital hyperpigmentation (POH) is a common benign condition affecting facial esthetics. This study evaluated the efficacy and safety of an injectable sodium hyaluronate complex solution combined with vitamin C, tranexamic acid, and glutathione for POH treatment. Method 120 POH patients were randomly divided into two groups. All participants received two treatment injections at two-week intervals. Evaluations were conducted at 4 and 12 weeks posttreatment, assessing periorbital grayscale values, clinical grading changes, Global Esthetic Improvement Score, Dermatologic Quality of Life Index (DLQI), and patient satisfaction. Result The treatment group demonstrated significant improvements in grayscale values (162.10 ± 14.22 to 169.66 ± 13.43) and reduced pigmentation differences from normal skin (23.01 ± 12.73 to 14.44 ± 14.79). The control group showed no significant changes. Treatment group patients exhibited significantly better grayscale values (p < .05), improved DLQI scores, and reduced dark circle severity (p < .05). 96.7% of treated patients reported satisfaction with visible esthetic improvements. Conclusion The hyaluronate-based combination therapy effectively improved POH, demonstrating significant esthetic enhancement and quality of life improvement. This minimally invasive approach proved safe, effective, and highly satisfactory, presenting a promising treatment option for periorbital hyperpigmentation. Evidence level Level II.

Quantifying the degree of modification (DoM) of hyaluronic acid (HA) is crucial for biomaterials development. This has remained a challenge, as diverse functional groups hinder precise spectroscopic quantification. Here, we present a method employing thermogravimetric analysis (TGA) by comparing residues of sodium hyaluronate (NaHA) and carboxylate-modified HA derivatives. Thermal decomposition enabled quantification of the inorganic residue (Na2CO3) that was obtained as the final product. Validation on four diverse HA derivatives, namely aldehyde, furan, thiol, and cyanoacetate, was performed. The first three matched 1H NMR/UV-vis data, while the cyanoacetate sample, previously unquantifiable, was determined for the first time. Because the residue arises solely from Na+, the assay is independent of the attached pendant group and potentially transferable to any carboxylate-bearing polymer beyond HA. Residue-based TGA closes an analytical gap, providing a label-free tool for quantifying carboxylate modification, applicable irrespective of chemical structure, and able to characterize "silent groups," relevant for biomaterials.

Sudden sensorineural hearing loss (SSNHL), often associated with tinnitus, significantly impacts individuals' quality of life. Current treatments, such as free drugs via intravenous or intratympanic (IT) administration of dexamethasone (DEX) and lidocaine, face limitations like low bioavailability and rapid drug clearance. To address these challenges, we developed a local co-delivery system combining DEX microcrystals (DEX MCs) and lidocaine-loaded poly(lactic-co-glycolic acid) (PLGA) non-spherical microparticles (LPNMs) for sustained drug release in the inner ear. DEX MCs and LPNMs were prepared using the traditional precipitation technique and double emulsion-solvent evaporation, respectively. After characterizing physicochemical properties and drug release kinetics, they were dispersed in sodium hyaluronate solution for IT injection, then invivo pharmacokinetics and biocompatibility in guinea pigs were studied. DEX MCs exhibited stable dissolution, while LPNMs provided sustained lidocaine release, reducing potential side effects. Invivo studies in guinea pigs demonstrated prolonged drug retention in the perilymph and improved pharmacokinetics. Histological evaluation confirmed the good biocompatibility of this combined delivery system, with no significant inner ear damage observed. This co-delivery system can be used as a depot for delivering both DEX and lidocaine to the inner ear and offers a promising approach for the synergistic treatment of SSNHL associated with tinnitus.

To evaluate the impact of using a high-viscosity hyaluronate solution in the fluid reservoir (FR) on post-lens fluid turbidity and the settling of scleral lenses (SLs). Forty-four eyes of 22 keratoconus patients were fitted SLs. SLs applied to the right eye were filled with preservative-free sodium hyaluronate solution, whereas those applied to the left eye were filled with preservative-free saline. After SL fitting, high- and low-contrast visual acuities (VAs) were measured at 0, 4, and 8 hr. The optical density of the post-lens fluid was calculated using Scheimpflug tomography and graded from anterior-segment optical coherence (AS-OCT) images. Central corneal clearance and lens settling were measured with AS-OCT. High-contrast VA showed no significant change over time in either group. Low-contrast VA remained stable during 8 hr of SL wear in the right eyes, but low-contrast VA decreased at 4th and 8th hours in the left eyes. AS-OCT-based turbidity grading and the optical density increased over time, with no difference between the two solutions. The rate and amount of settling did not differ between the groups. High-viscosity sodium hyaluronate may sustain improved low-contrast vision in keratoconus patients compared with saline, without adversely affecting post-lens fluid turbidity or lens settling.

Aging leads to structural and compositional changes in the skin, contributing to more wrinkles, less smoothness, and dryness. There is growing interest in oral non-invasive interventions to help ameliorate visual signs of skin aging. The purpose of this study was to evaluate the efficacy of an oral skincare supplement containing hyaluronic acid and wheat oil extract on parameters of skin aging in a diverse population. Healthy adults (ages 26-64) were recruited and randomly assigned to the intervention group (n = 31) or placebo group (n = 32). The intervention group received an oral skincare supplement consisting of wheat oil extract and low molecular weight sodium hyaluronate, with a 12-week follow-up period. The intervention group demonstrated a significant reduction in crow's feet wrinkles and improvements in both facial and global skin smoothness beginning at week8 and continuing to week12, compared to the placebo group. Additionally, the intervention group exhibited significant increases in skin hydration and elasticity in the leg region relative to the placebo group. Dermatologists' evaluations revealed significant reductions in global scores of both deep and fine wrinkles from baseline to week12, but only in the intervention group. By week12, a greater proportion of participants in the intervention group reported improvements in fine lines and wrinkles, skin radiance/glow, skin resilience/elasticity, and overall signs of aging, with these changes being significantly different from the placebo group. An oral skincare supplement combining wheat oil extract and hyaluronic acid offers a comprehensive method for addressing skin aging, providing measurable clinical improvements in various skin parameters and enhancing subjective perceptions of skin health and appearance. ClinicalTrials.gov identifier, NCT06083402.

Background:Cross-linked hyaluronic acid dermal fillers are being used increasingly for aesthetic enhancements, including lip enhancement, cheekbone augmentation, and nasolabial fold improvement. This study aimed to assess the safety and performance of a newly introduced dermal filler across different skin types.Methods:This is a prospective, single-arm clinical study that evaluates the safety and effectiveness of cross-linked sodium hyaluronate injection in patients undergoing treatment for facial wrinkles and lip enhancement. Participants underwent assessments at baseline; immediately at postoperative day 0; and at 3 months, 6 months, and 1 year after the procedure. The safety and effectiveness were evaluated through physical examinations, wrinkle severity ratings, full face global aesthetic assessments, cheekbone augmentation, nasolabial fold severity, and lip enhancement evaluations.Results:The study cohort included 122 participants, 41 men and 81 women, predominantly with Fitzpatrick skin types 3 (59%) and 4 (41%). Physical examinations revealed a significant reduction in facial wrinkles, with 81.14% (left side) and 84.42% (right side) of patients showing no wrinkles after 1 year. Full face aesthetic improvements were noted, with 36.88% of patients being “very much improved.” Cheekbone augmentation showed no wrinkles in 55.74% of patients (left side) and 72.13% (right side) at 1 year. Nasolabial fold severity decreased most significantly between 6 months and 1 year.Conclusions:The novel cross-linked hyaluronic acid dermal filler is safe and effective for enhancing lips, augmenting cheekbones, and improving nasolabial folds across various skin types. Significant improvements were observed in wrinkle severity, overall facial aesthetics, and specific enhancement areas.

Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas (KORTUC) is a novel radiosensitizing treatment developed in Japan that involves intratumoral injections of hydrogen peroxide (H2O2) and sodium hyaluronate (HA). KORTUC II, an evolved form of the therapy, aims to enhance radiotherapy efficacy by locally increasing oxygen tension and inhibiting antioxidant enzymes in the tumor microenvironment. This study retrospectively evaluated the safety and efficacy of KORTUC-based breast-conserving therapy (KORTUC-BCT) in patients with stage 0-IIIC primary breast cancer who refused standard treatment protocols. A total of 50 patients who underwent KORTUC-BCT between February 2013 and April 2022 and had at least 1 year of follow-up were included. Radiotherapy consisted of short-course tangential irradiation at a dose of 44 Gy in 16 fractions. For patients with lymph node metastases, the supraclavicular region was included in the radiation field. A boost dose of 9–12 Gy was subsequently delivered to the tumor using electron-beam radiation therapy. The H2O2/HA sensitizer was intratumorally injected twice weekly under ultrasound guidance. All patients achieved a clinical complete response within a median evaluation time of 12 months. The 3-year local control rate for all cases was 89.3%; by stage, it was 100% for 0-I, 100% for IIA, 53.3% for IIB, 75% for IIIA, 75.0% for IIIB and 100% for stage IIIC. The 3-year disease-free survival rate was 75% overall; by stage, it was 100% for 0-I, 91.7% for IIA, 53.3% for IIB, 60.0% for IIIA, 75.0% for IIIB and 20.0% for IIIC. Lymph node metastasis sites had a 100% 3-year control rate. No grade ≥3 adverse events or cosmetic complications were observed. These findings suggest that KORTUC-BCT is a minimally invasive and well-tolerated therapy with promising outcomes, particularly for patients with early-stage breast cancer who decline surgery. This clinical study was registered in the UMIN clinical trials registry (UMIN000003734; June 10, 2010).

Introduction. Pregnant women are objects of special attention of physicians due to two main reasons. The first one is that the fetal life depends on the health and quality of life of a future mother. The second is associated with increased load on all organs and systems of the female body, including the organ of vision. However, manifestations of dry eye syndrome (DES) in this contingent are often not given due attention and often remain untreated, which has a negative impact on the quality of life of women during this difficult period and can lead to diseases of the anterior segment of the eye. The aim of the study was to evaluate the effectiveness of a drug based on sodium hyaluronate 0.21 % in pregnant women with dry eye syndrome due to dysfunction of the meibomian glands. Рatients and methods. The study included 60 patients (120 eyes) with dry eye syndrome with an average age of 31.45 ± 5.98 years and a follow-up period of 3 months. There were 2 groups of patients: the main group (pregnant women with DES) and the control group (non-pregnant women with DES). Patients of both groups were administered a preservative-free form of 0.21 % sodium hyaluronate three times a day for 3 months. All studied patients underwent standard methods of examination, indicators of DES were assessed along with an objective valuation of tear film parameters and meibomian glands condition by digital biomicroscopy on a MediWorks slit lamp (Precision Instruments Co., Ltd., Shanghai) at the time of first visit and at 1 and 3 months of follow-up. Results and discussion. A comparative analysis of therapy effectiveness in the main and control groups showed that OSDI scores (ocular surface disease index), non-invasive tear breakup time (NITBUT) and meibomian gland function improved after treatment in both groups. Early diagnosis and timely correction of DES manifestations in pregnant women by administration of tear replacement therapy with preservative-free sodium hyaluronate 0.21 %, as well as eyelid hygiene can improve the quality of life of this group of patients and prevent associated with DES complications. Conclusion. The selected preservative-free tear replacement therapy with sodium hyaluronate 0.21 % (Optinol® Express moisturizing) provided a combination of ocular surface moisturizing and reducing the risk of inflammatory lesions with facilitating the release of meibomian gland secretion, contributing to the effectiveness and prolongation of therapy.

Evaluation of computer-guided visco-supplementation in the management of internal derangement of temporomandibular joint: a randomized controlled clinical trial.